Crossmark

Different dosing regimens for chronic knee osteoarthritis (KOA) pain management: A pooled analysis on celecoxib

Crossref DOI link: https://doi.org/10.1007/s40520-025-03302-2

Published Online: 2026-01-23

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Choy, Ernest

Fuggle, Nicholas

Biesheuvel, Egbert

Venugopal, Srinivasan

Kumbhar, Sagar Suresh

Chiaese, Raffaella Maria Rita

Walker, Chris https://orcid.org/0000-0001-9132-8965
Reginster, Jean-Yves
Funding

Funding for this research was provided by:

Viatris
License Information

Text and Data Mining valid from 2026-01-23

Version of Record valid from 2026-01-29
More Information

Article History

Received: 3 December 2025

Revised: 18 December 2025

Accepted: 18 December 2025

First Online: 23 January 2026

Declarations

:

: EC has received support and/or received grants and/or a paid consultant and/or received payment or honoraria and/or is an editor of and/or owns stocks and/or recipient of miscellaneous services from Viatris, Pfizer, BioCancer, Sanofi, Abbvie, Biogen, Fresenius Kabi, Editor of Rheumatology (Oxford), and Inmedix. NF received payment or honoraria from Viatris, Amgen, and UCB. EB is an employee and owns stocks in Viatris. SV is an employee of Viatris. SSK is an employee of Viatris. RMRC is an employee of Viatris. CW is an employee of Viatris. JYR has received support and/or a paid consultant and/or received payment or honoraria and/or received Support for attending meetings and/or travel and/or Participation on Advisory Board of Viatris. JYR is Deputy Editor of ACER but has not taken part in the assessment and publication process of this manuscript.

: Patients or the public were not involved in the design, or conduct, or reporting, or dissemination plans of our research.

Document is current

Any future updates will be listed below